CL2021000736A1 - Receptor de antígeno quimérico. - Google Patents

Receptor de antígeno quimérico.

Info

Publication number
CL2021000736A1
CL2021000736A1 CL2021000736A CL2021000736A CL2021000736A1 CL 2021000736 A1 CL2021000736 A1 CL 2021000736A1 CL 2021000736 A CL2021000736 A CL 2021000736A CL 2021000736 A CL2021000736 A CL 2021000736A CL 2021000736 A1 CL2021000736 A1 CL 2021000736A1
Authority
CL
Chile
Prior art keywords
antigen receptor
chimeric antigen
car
antigen
binds
Prior art date
Application number
CL2021000736A
Other languages
English (en)
Inventor
Martin Pulé
Shaun Cordoba
Simon Thomas
Shimobi Onuoha
Lim Wen Chean
Biao Ma
Mathieu Ferrari
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1815775.0A external-priority patent/GB201815775D0/en
Priority claimed from GBGB1902021.3A external-priority patent/GB201902021D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CL2021000736A1 publication Critical patent/CL2021000736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención provee un receptor antigénico quimérico (CAR) que se une a un antígeno objetivo en baja densidad, el cual comprende un dominio de unión a antígenos Fab. La invención también se refiere a células que expresan este CAR, y a su uso en el tratamiento de enfermedades.
CL2021000736A 2018-09-27 2021-03-24 Receptor de antígeno quimérico. CL2021000736A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1815775.0A GB201815775D0 (en) 2018-09-27 2018-09-27 Chimeric antigen receptor
GBGB1902021.3A GB201902021D0 (en) 2019-02-14 2019-02-14 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
CL2021000736A1 true CL2021000736A1 (es) 2021-08-20

Family

ID=68084861

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000736A CL2021000736A1 (es) 2018-09-27 2021-03-24 Receptor de antígeno quimérico.

Country Status (13)

Country Link
US (2) US20220033509A1 (es)
EP (1) EP3856775A2 (es)
JP (2) JP7458382B2 (es)
KR (1) KR20210066865A (es)
CN (1) CN112771076B (es)
AU (1) AU2019348975A1 (es)
BR (1) BR112021004986A2 (es)
CA (1) CA3113896A1 (es)
CL (1) CL2021000736A1 (es)
IL (1) IL281428A (es)
MX (1) MX2021003636A (es)
SG (1) SG11202102781UA (es)
WO (1) WO2020065330A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114585A1 (en) 2008-03-12 2009-09-17 Imclone Llc Anti-tyrp1 antibodies
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CA2930215C (en) 2013-11-21 2021-04-27 Ucl Business Plc A cell comprising more than one chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CN106687483B (zh) * 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
ES2878449T3 (es) * 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
JP7174522B2 (ja) 2014-12-05 2022-11-17 メモリアル スローン ケタリング キャンサー センター Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
US20170362297A1 (en) 2014-12-19 2017-12-21 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
CN107980046B (zh) * 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
JP2018522833A (ja) * 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
WO2017156479A1 (en) * 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor

Also Published As

Publication number Publication date
JP2022502036A (ja) 2022-01-11
AU2019348975A1 (en) 2021-03-25
EP3856775A2 (en) 2021-08-04
CA3113896A1 (en) 2020-04-02
SG11202102781UA (en) 2021-04-29
WO2020065330A3 (en) 2020-05-14
KR20210066865A (ko) 2021-06-07
MX2021003636A (es) 2021-07-21
WO2020065330A2 (en) 2020-04-02
CN112771076A (zh) 2021-05-07
JP7458382B2 (ja) 2024-03-29
CN112771076B (zh) 2024-04-02
BR112021004986A2 (pt) 2021-06-08
IL281428A (en) 2021-04-29
US20220356260A1 (en) 2022-11-10
US20220033509A1 (en) 2022-02-03
JP2023169370A (ja) 2023-11-29

Similar Documents

Publication Publication Date Title
CL2021000736A1 (es) Receptor de antígeno quimérico.
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112018015670A2 (pt) construtos de anticorpo biespecíficos envolvendo células t
BR112017022838A2 (pt) receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
CU24475B1 (es) Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1
DOP2019000062A (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MY191894A (en) Antibodies that bind zika virus envelope protein and uses thereof
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
WO2018231339A3 (en) TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
CO2021008755A2 (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización
MX2018009218A (es) Anticuerpos de cgrp y sus usos.